You really are boring. ODD is relatively straight forward to achieve, but it is also quite inconsequential. If you were trying to compare FDA approval for orphan indications versus non orphan then I think that has been answered here(with references) on more than one occasion.
Clinuvel published a 20 page newsletter today and this is your retort! You need new talking points otherwise you will lose your audience. Keep trying we appreciate your persistence.
Ann: CLINUVEL Newsletter III - June 2022, page-3
Add CUV (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$14.64 |
Change
0.060(0.41%) |
Mkt cap ! $731.6M | |||
| Open | High | Low | Value | Volume |
| $14.61 | $14.99 | $14.40 | $618.9K | 42.44K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 11 | 397 | $14.60 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $14.64 | 373 | 12 |
View Market Depth
| Last trade - 12.03pm 10/07/2024 (20 minute delay) ? |
| CUV (ASX) Chart |